Dr Sophia Karagiannis and her team
Triple negative breast cancer is a sub-type of the disease for which there are currently no targeted treatments. In addition, this form of breast cancer can be more aggressive than others. We need to understand what makes triple negative breast cancer different from other breast cancers so that drug targets can be identified that will lead to the development of effective targeted treatments for patients.
Dr Sophia Karagiannis aims to use scientific advances made at the King’s College London Research Centre to develop antibodies (naturally occurring proteins which recognise and destroy pathogens such as bacteria and cancer cells), which specifically recognise triple negative breast cancer cells. In the future, these antibodies may become used as clinically effective drugs as well as being used to more accurately diagnose triple negative breast cancer.
The team hopes that this work will help produce the next generation of breast cancer drugs specifically targeted towards triple negative breast cancer.
What difference will this project make?
There are currently no targeted treatments available for patients with triple negative breast cancer. Dr Karagiannis’s research in collaboration with Professor Andrew Tutt and Professor Tony Ng at the King’s College London Research Centre could lead to the development of new and effective drugs for triple negative breast cancer.
Make a donation to support our research
Help fund the future of research now to stop women dying from breast cancer.